|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on June 28, 2002; DOI 10.1182/blood-2001-11-0039.
TRANSPLANTATION
From the Unité de Thérapie
Tissulaire, Cellulaire et Génique, and the Laboratoire de
Thérapeutique Immuno-Moléculaire, INSERM E 0119/UPRES EA
2284, Etablissement Français du Sang
Bourgogne-Franche-Comté, Besançon, France; Service
d'Epidémiologie et de Biostatistique and the Unité de
Médecine Transfusionnelle et d'Hémovigilance, Institut
Gustave Roussy, Villejuif, France; Service d'Hématologie
Clinique, Hôpital Edouard Herriot, Lyon, France; Service
des Maladies du Sang, Centre Hospitalier Universitaire, Angers, France;
Service d'Hématologie Clinique, Centre Hospitalier
Universitaire, Grenoble, France; Service d'Hématologie Clinique
d'Oncologie et de Thérapie Cellulaire, Centre Hospitalier
Universitaire, Etablissement Français du Sang Centre-Atlantique,
Poitiers, France; Unité de Transplantation Médullaire,
Institut Paoli Calmettes, Marseille, France; and the Service
d'Hématologie, Hôpital Henri Mondor, Créteil,
France.
We have recently shown that the use of allogeneic granulocyte
colony-stimulating factor (G-CSF)-mobilized peripheral blood hematopoietic stem cell transplantation (PBHSCT), as compared with bone
marrow transplantation (BMT), is associated with increased titers of
antibodies (Abs) directed against red blood cell ABO antigens.
To further evaluate the influence of a G-CSF-mobilized PBHSCT graft on
alloimmune Ab responses, we examined the frequency of anti-HLA Abs
after transplantation in the setting of the same randomized study,
comparing PBHSCT with BMT in adults. Anti-HLA Ab presence was
determined by complement-dependent cytotoxicity assay (CDC) and
flow cytometry in the recipient before and 30 days after
transplantation as well as in the donor before graft donation. The use
of PBHSCT was significantly associated with increased
detection of anti-HLA immunoglobulin G (IgG) Abs early after
transplantation as evidenced by flow cytometry (11 of 24 versus 4 of 27 transplant recipients, P = .03) and, less so, by CDC (5 of 24 versus 1 of 27 transplant recipients,
P = .09). The difference between PBHSCT
and BMT was further heightened when analysis was restricted to anti-HLA
IgG Ab-negative donor/recipient pairs. In such a setting,
early anti-HLA Ab was never detected after BMT but was
repeatedly detected after PBHSCT (flow cytometry, 6 of 18 versus 0 of
17 transplant recipients, P = .02; CDC, 4 of 23 versus 0 of 26 transplant recipients, P = .04). Importantly, the
PBHSCT-associated increase in anti-HLA Ab detection was observed despite a reduction in the median number of platelet-transfusion episodes per patient in PBHSC transplant versus BM transplant recipients (3 platelet-transfusion episodes [range, 1-21] in PBHSCT group vs 6 platelet-transfusion episodes [range, 3-33] in the BMT
group; P = .02). In conclusion, this study
strongly suggests that G-CSF-mobilized PBHSCT results in an increased
incidence of circulating anti-HLA Abs and further confirms that the use of such a graft alters alloimmune Ab responses.
(Blood. 2002;100:1484-1489) Use of peripheral blood stem cells after
granulocyte colony-stimulating factor (G-CSF) mobilization for
autologous or allogeneic hematopoietic stem cell (HSC) transplantation
is being increasingly considered.1-11 We and others have
demonstrated that the use of such a graft has a significant impact on
the number and function of immune cells present in the graft as well as
on posttransplantation immune reconstitution when compared with a bone
marrow (BM) graft.8,12-17 In particular, we have recently
shown that use of allogeneic G-CSF-mobilized peripheral blood HSC
transplantation (PBHSCT) can alter an alloimmune antibody (Ab)
response, as evidenced by increased titers of Ab directed against red
blood cell (RBC) ABO antigen (Ag) after PBHSCT when compared with BM
transplantation (BMT).16 Such an altered immunohematological reconstitution after transplantation can have profound clinical consequences, as evidenced by the occurrence of
severe hemolysis after minor ABO-incompatible
PBHSCT.18-23
To further evaluate the influence of a G-CSF-mobilized PBHSC
graft on the occurrence of anti-HLA Abs after transplantation, we have
taken advantage of the multicenter randomized phase III clinical trial comparing allogeneic BMT to allogeneic PBHSCT conducted by the Société Française de Greffe de Moelle et de
Thérapie Cellulaire7 (Paris, France) to prospectively
compare the frequency of anti-HLA Ab detection after allogeneic PBHSCT
versus BMT.
Patients and blood sample collection
Clinical study
Platelet concentrate and RBC concentrate transfusion HSC donor and recipient ABO-compatible RBC concentrates (RBC-Cs) were transfused when the hemoglobin level was below 80 g/L (8 g/dL) according to transfusion practices previously described.24 Single-donor platelet concentrates (PCs) were administered to treat or prevent hemorrhage when blood platelet counts were below 20 × 109/L. All RBC-Cs and PCs were leuko-reduced by prestorage filtration. The number and time of administration of PCs and RBC-Cs were recorded for all recipients. Similarly, administration of intravenous polyvalent immunoglobulin (IVIG) was documented.Biological samples Serum samples (Vacutainer; Becton Dickinson, Le Pont de Claix, France) were obtained from the BM donors before or at the time of BM harvest (n = 27); from the PBHSC donors before and/or after G-CSF mobilization (before the first apheresis) (n = 24); as well as from all recipients before the conditioning regimen and at day +30 after transplantation (n = 51). In addition, whenever possible, "long-term" serum samples were obtained from BM (n = 9) or PBHSC (n = 9) recipients from 1 to 2 years after transplantation. Blood samples were shipped by overnight mail to the Etablissement Français du Sang Bourgogne-Franche-Comté (Besançon, France), and sera were immediately cryopreserved.Anti-HLA Ab detection The presence of anti-HLA Ab was determined by the classical Terasaki complement-dependent cytotoxicity assay (CDC)25 and by flow cytometry (Flow-PRA; One-Lambda, Canoga Park, CA).26-28 The latter method, recently developed, detects both anti-HLA class I and anti-HLA class II immunoglobulin G (IgG) Ab with a higher sensitivity as compared with CDC.28The CDC assays were performed as previously described25 and involved the testing of serum samples against a panel of previously cryopreserved peripheral blood mononuclear cells from 30 HLA-typed donors. Serum samples were considered positive for anti-HLA Ab if they reproducibly caused at least 60% cytotoxicity in 1 or more cell populations or at least 40% cytotoxicity in 2 or more cell populations of the panel. In such cases, positivity was confirmed on a second panel of 30 different HLA-typed donors and tested in the presence or absence of dithiothreitol (DTT). Anti-HLA IgG Ab positivity persisted despite treatment with DTT, while the presence of IgM Abs resulted in no cytotoxicity in the presence of DTT. Panel reactivity was calculated as a percentage of the number of reactive cell populations among the panel. Because the serum samples were also tested by flow cytometry with the use of a method that allows a clear distinction between anti-HLA class I and anti-HLA class II IgG Abs, CDC testing against purified HLA-typed B cells after absorption on platelets was not performed. Flow-PRA (One-Lambda) assays were performed according to the supplier's recommendations. Briefly, 20 µL test serum was incubated for 30 minutes with 5 µL class I and 5 µL class II beads at 22°C. The beads were then washed twice with buffer and incubated for 30 minutes with 100 µL fluorescein isothiocyanate-conjugated goat anti-human IgG at 22°C in the dark. After 2 additional washings, the beads were fixed in 1% paraformaldehyde buffer. In each assay, pooled AB-sera known to be devoid of anti-HLA Ab (checked by CDC and flow cytometry on 3 different populations) was used as a negative control, whereas pooled sera containing polyspecific anti-HLA Ab was used as a positive control. Analysis was done with a FACS-Scan (Becton Dickinson) on a 1024-channel linear scale. In the assays performed to determine a standardized cutoff value for class I or class II beads, tests were performed with a negative-control serum pool, and the threshold fluorescence intensity limit was arbitrarily set at the end of the peak. With such a threshold, 5% of the beads in the presence of the negative-control serum pool were found to be positive.28 Detection of rheumatoid factors Quantitative determination of serum rheumatoid factor (RF) was performed by nephelometry and hemagglutination. Nephelometry measured the endpoint aggregation of small latex particles coated with human IgG (N Latex RF kit and BNII nephelometer; Dade Behring, Marburg, Germany). The microplate hemagglutination technique (Laboratoires Fumouze, diagnostics division, Levallois-Peret, France) was based on the principle of the Waaler-Rose reaction29 and used sheep erythrocytes sensitized by the IgG fraction of rabbit anti-sheep erythrocyte serum. That technique discriminates RF and nonspecific heteroantibodies. RF serum titers were determined by the highest serum dilution giving hemagglutination. Each batch was titrated in international units by milliliter according to the international reference preparation of rheumatoid arthritis serum30; RF titers were expressed as international units per milliliter and, according to the manufacturer's instructions, were considered significant when higher than 12 IU/mL.Statistical analysis Continuous variables were compared in the 2 groups with the use of Wilcoxon rank-sum test. Qualitative variables were analyzed with a chi-square test or Fisher exact test when expected frequencies were lower than 5. The potential confounding effect of covariables on the relation between the source of HSCs and the first detected anti-HLA Ab (de novo anti-HLA Ab) in the recipient at day +30 were studied one by one by bivariate analysis (Mantel-Haenszel or Fisher exact test for qualitative variables and exact logistic regression for quantitative variables).
Prior to transplantation, anti-HLA IgG Abs were present in 3 of 24 PBHSC transplant recipients (0 of 24 by CDC, 3 of 24 by Flow-PRA) and in 7 of 27 BM transplant recipients (1 of 27 by CDC, 7 of 27 by Flow-PRA). In addition, anti-HLA IgG Abs were found in 3 of 24 PBHSC transplant donors before G-CSF treatment (1 of 24 by CDC, 3 of 24 by Flow-PRA) and in 2 of 27 BM transplant donors (0 of 27 by CDC, 2 of 27 by Flow-PRA). All 5 HLA-immunized donors were women, with 4 of them having a history of pregnancy (3 of 3 in the PBHSCT group, 1 of 2 in the BMT group). Anti-HLA Abs were never simultaneously detected in the recipient (before transplantation) and in the donor. Determination and titration of anti-HLA Abs before and after G-CSF treatment were performed in 19 PBHSC transplant donors. Treatment by G-CSF did not result in the early (within 24 hours after the end of G-CSF treatment) appearance of anti-HLA Ab in any of the 16 anti-HLA-negative (pre-G-CSF) donors. The 3 donors with anti-HLA IgG Abs before G-CSF treatment had similar Ab titers after G-CSF. However, in one of these donors, post-G-CSF evaluation revealed, in addition to a known anti-HLA class II IgG Ab immunization, the presence of an anti-HLA class I IgG Ab. The use of a PBHSC allogeneic graft was associated with an increased
frequency of anti-HLA IgG Abs detected at day 30 (Tables 2 and 3).
The increased frequency of anti-HLA IgG Abs did not reach significance
when Abs were detected by CDC (5 of 24 in PBHSC transplant
recipients versus 1 of 27 in BM transplant recipients, P = .09) (Table 2). However, when Abs were
detected by flow cytometry, PBHSCT was significantly associated
with an increased frequency of anti-HLA Abs (11 of 24 PBHSC transplant
recipients versus 4 of 27 BM transplant recipients,
P = .03). Anti-HLA IgG Abs were directed against both HLA
class I Ags (10 of 24 transplant recipients after PBHSCT versus 3 of 27 after BMT, P = .02) and/or HLA class II Ags (5 of 24 versus 1 of 27 transplant recipients, P = .09) (Table 3).
In 4 patients, all from the PBHSCT group, both IgG class I and IgG
class II HLA Abs were detected.
To more accurately measure the influence of the type of HSC graft on the de novo occurrence of anti-HLA Abs after PBHSCT or BMT, we restricted our analysis to anti-HLA Ab-negative recipients (prior to transplantation) having received a graft from an anti-HLA Ab-negative donor. In this group of recipients, the early presence of anti-HLA IgG Ab was detected only after PBHSCT and never after BMT. The association between a PBHSCT graft and the increased occurrence of anti-HLA IgG Abs was confirmed in this group of recipients both by CDC (4 of 23 in PBHSC transplant recipients versus 0 of 26 in BM transplant recipients, P = .04) and by flow cytometry (anti-HLA class I Abs, 7 of 20 after PBHSCT versus 0 of 20 after BMT, P = .008; anti-HLA class II Abs, 1 of 19 versus 0 of 22, P = .46) (Tables 2 and 3). De novo occurrence of both anti-HLA class I and II IgG Abs were observed in one PBHSC transplant recipient. When the recipient had detectable anti-HLA class I and/or class II IgG Abs prior to transplantation (3 of 24 PBHSC transplant recipients, 7 of 27 BM transplant recipients), such Abs were detected at day 30 after transplantation in 2 of 3 PBHSC transplant recipients versus 3 of 7 BM transplant recipients. On the other hand, the presence in the donor of anti-HLA class I and/or class II IgG Abs before graft harvest (3 of 24 PBHSC donors, 2 of 27 BM donors) was associated with the detection of anti-HLA IgG Abs at day 30 in 3 of 3 PBHSC transplant recipients and 1 of 2 BM transplant recipients. Finally, when the donor had anti-HLA Abs with identified HLA specificity, similar Ab specificity was found in the recipient when Abs were present at day 30 (data not shown). PBHSCT was also associated with an increased incidence of anti-HLA IgM Ab after PBHSCT versus after BMT (8 of 24 PBHSC transplant recipients versus 0 of 27 BM transplant recipients, P = .001). This finding also persisted after the exclusion of the sole recipient (BMT recipient) who received a graft from a donor with anti-HLA IgM Ab: 8 of 24 PBHSC transplant recipients versus 0 of 26 BM transplant recipients (P = .001) (Table 2). No anti-HLA IgM Abs were found in recipients before transplantation. In addition to pretransplantation anti-HLA immune status, both
BMT and PBHSCT donor/recipient groups were compared for a number of
parameters that might have induced the occurrence of anti-HLA Ab 30 days after transplantation. As detailed in Table 1, pretransplantation parameters such as age, sex and sex mismatch, previous pregnancy, diagnosis, and conditioning regimen did not differ significantly in the
2 groups. Three posttransplantation parameters could
significantly influence the occurrence of anti-HLA Ab: IVIG treatment,
RBC-C transfusions, and PC transfusions (Table
4). IVIG treatment and RBC-C transfusion
did not significantly differ in the PBHSCT and BMT groups. In contrast,
the median number of PC transfusion episodes was significantly lower in
the PBHSCT group than in the BMT group (3 platelet-transfusion episodes
[range, 1-21] in PBHSCT group vs 6 platelet-transfusion episodes
[range, 3-33] in the BMT group; P = .02). After
adjustment for each of the potential confounding variables in bivariate
analyses, the use of a PBHSC graft remained significantly associated
with an increased frequency of de novo anti-HLA IgG (CDC and Flow-PRA,
class I) as well as IgM Abs.
The occurrence of anti-HLA Abs after hematopoietic
transplantation has been reported31 and could result from
the passive transfer of anti-HLA Ab (prior presence in the recipient;
plasma and/or IVIG administration) or from donor transfer of a
known or unknown (ie, undetected) anti-HLA immunity. To further explore this last issue, we examined, within the group of PBHSC transplant recipients with no detectable pretransplant recipient or donor anti-HLA
immunization, whether the presence of anti-HLA Abs indeed occurred more
frequently when there was a female donor with a known history
of pregnancy. No evidence for significant association was
found. However, there was indeed a trend for a higher
frequency of de novo immunization when the donor was a female with a
history of pregnancy versus a male donor or a female donor with no
known history of pregnancy (CDC, 3 of 7 versus 1 of 16, P = .07; Flow-PRA anti-HLA class I, 4 of 7 versus 3 of 13, P = .17) (Table 5). Furthermore, 2 recipients with de novo presence of anti-HLA Ab at day
30 received a graft from a male donor with no prior transfusion history, thus suggesting that de novo posttransplantation immunization also contributed
In view of the significant association between the use of PBHSC graft and the occurrence of serum anti-HLA IgM Ab after transplantation, we chose to evaluate the possible influence of the type of HSC graft on the appearance of nonalloreactive IgM Ab such as RF. At 30 days after transplantation, the presence of RF was detected in only 1 of 18 PBHSC transplant recipients and in 1 of 20 BM transplant recipients. RF titers were high in the PBHSC transplant recipient (latex, 91.3 IU/mL; Waaler-Rose, 512 IU/mL) but borderline positive in the BM transplant recipient (latex, 13 IU/mL; Waaler-Rose, below 8 IU/mL). Serum samples collected between 1 and 2 years after transplantation were available for a limited number of recipients (n = 18). Flow-PRA analysis revealed the presence of anti-HLA Abs in 1 of 9 PBHSC graft recipients and in 1 of 9 BM graft recipients.
In our study, the use of an allogeneic PBHSC graft was
associated with an increased frequency of anti-HLA Abs 30 days after transplantation as compared De novo detection of circulating anti-HLA Abs tended to occur with a higher frequency in female donors with a history of pregnancy versus male donors or female donors with no known history of pregnancy. This finding suggests that after PBHSCT, previously unknown immunization may have been boosted by the use of a G-CSF-mobilized graft and posttransplantation RBC-c or PC transfusion. On the other hand, among the donors of the PBHSC transplants to the recipients with first detected anti-HLA Abs, 2 out of 7 were male donors with no history of transfusion or intravenous drug use. Such a finding suggests the possible occurrence of primary anti-HLA alloimmunization after PBHSCT despite the reduced PC transfusion requirements and the systematic use of leuko-reduced blood products. However, in both cases, the limited number of informative recipients or donors prevents any definitive conclusion. Because PBHSCT was associated with accelerated platelet reconstitution, any deleterious effects on platelet transfusion requirements related to the increased presence of anti-HLA Abs might not be discernible. Furthermore, the accelerated hematopoietic reconstitution associated with PBHSCT might have prevented any measurable anti-HLA Ab-related decrease in transfusion efficacy. Finally, all patients included in our study received methotrexate at days 1, 3, and 6 after transplantation. Methotrexate is cytotoxic for B lymphocytes32 and might have contributed to the delay of the appearance of anti-HLA Abs until after platelet reconstitution. As mentioned earlier, we have observed that the use of a PBHSC graft was also associated with increased anti-A and/or anti-B Ab titers early after transplantation.16 Such increased Ab titers probably account for the occurrence of several acute hemolysis episodes after allogeneic PBHSCT in the setting of a "minor" ABO mismatch and the absence of methotrexate in the GvHD prophylaxis regimen.18-23 These hemolysis episodes occurred most often between day 8 and day 14 after PBHSCT and were associated with the production of Abs directed at ABO Ags present on recipient RBCs. In this respect, we have shown that PBHSC recipients indeed exhibited significantly increased anti-A and/or anti-B Ab titers at day 30 following PBSCT and particularly in the setting of a minor ABO mismatch.16 While it seems most likely that the increased anti-HLA antibody production is donor derived, formal proof is lacking. The number of B cells circulating at day 30 is too low, to allow for B-cell chimerism determination. Furthermore, isolating the anti-HLA Ab among the serum Ig for subsequent GM typing is a difficult task and would have required larger serum samples. Quantitative and qualitative differences between PBHSC and BM grafts13,14 could contribute to such an increase in early anti-HLA Ab or anti-AB Ab responses after PBHSCT. The higher number of B cells (especially those expressing CD45RO, CD25, or CD23 activation markers), T cells, and monocytes present in the PBHSC harvest, as compared with BM graft, could be associated with an enhanced Ab production early after PBHSCT. Furthermore, we15 and others17 have also found that, early after transplantation, peripheral blood counts of most lymphocyte subsets, including CD4 T cells and B cells, were higher in PBHSC graft recipients. We have previously demonstrated that G-CSF mobilization enhances the expression of CD45RO by CD19+ cells contained in the graft.14 Acquisition of CD45RO expression by cells has been associated with in vivo or in vitro B-cell transition from mature B-cell stage to early preplasma cells.33,34 Therefore, G-CSF mobilization could have a "priming" effect on B cells and render these cells more susceptible to Ag-induced activation than BM-associated B cells. The observation in vitro that G-CSF enhanced Ig generation, rather than B-cell proliferation,35 further strengthens this hypothesis. G-CSF-induced TH2 cytokine profile of the T cells present
in the graft could possibly also contribute to enhance post-PBHSCT Ab
responses.36,37 We have determined that the frequency of interferon- Overall circulating immunoglobulin levels were found to be similar 80 days after PBHSCT versus after BMT in a study recently reported by Storek et al.17 We were unable to detect an increased occurrence of circulating RF early after PBHSCT. To determine whether or not increased Ab response early after PBHSCT is preferentially directed against allogeneic Ags will require additional studies. An increased incidence of chronic GvHD after PBHSCT when compared with BMT has been observed in our study7 and confirmed in a recent meta-analysis.11 Since chronic GvHD is characterized by the frequent occurrence of Ab-mediated autoimmunelike syndromes,42 it is tempting to speculate that such a higher incidence of chronic GvHD may result, at least in part, from the higher level of B-cell activation and/or higher number of circulating B cells after PBHSCT with consequently increased Ab responses. In conclusion, our study strongly suggests that G-CSF-mobilized PBHSCT results in an increased incidence of anti-HLA immunization and further confirms that the use of different hematopoietic stem cell sources is associated with distinct immune-reconstitution patterns. Further dissection of such differences should contribute to enhancing the quality of clinical practice in patients requiring allogeneic HSC transplantation.
We wish to acknowledge the contribution of the following BMT centers, all in France: Angers, N. Ifrah, N. Piard; Besançon, J. Y. Cahn; Bordeaux, J. M. Boiron, B. Daze; Grenoble, F. Chenais; Hôtel-Dieu (Paris), B. Rio, M. F. Fruchart; Lille, J. P. Jouet, P. Renom; Nancy, F. Witz; Nantes, N. Milpied, B. David; Pitié Salpétrière (Paris), L. Sutton, A. Verdier; Saint-Etienne, C. Oriol; Toulouse, M. Attal, C. Payen, F. Roubinet; Institut Gustave Roussy (Villejuif), J. H. Bourhis, J. L. Pico; Poitiers, A. Sadoun; Robert Debré (Paris), M. Duval, F. Sellami. We also would like to acknowledge F. Bassompierre (Direction Régionale de la Recherche Clinique des Hôpitaux de l'Assistance Publique de Paris) for providing data pertaining to intravenous polyvalent Ig administration.
Submitted November 27, 2001; accepted April 3, 2002.
Prepublished online as Blood First Edition Paper, June 28, 2002; DOI 10.1182/blood-2001-11-0039.
Supported by grants from L'Etablissement Français des Greffes (No. 005610), L'Association pour la Recherche sur le Cancer (No. 9552), and La Fondation de France (No. 99004035).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Valérie Lapierre, Unité de Thérapie Tissulaire, Cellulaire et Génique, Etablissement Français du Sang Bourgogne-Franche-Comté, 1 Boulevard Fleming, BP 1937, 25000 Besançon, France; e-mail: valerie.lapierre{at}efs.sante.fr.
1.
Goldman J.
Peripheral blood stem cells for allografting.
Blood.
1995;85:1413-1415
2.
Bensinger WI, Weaver CH, Appelbaum FR, et al.
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.
Blood.
1995;85:1655-1658
3.
Körbling M, Przepiorka D, Huh YO, et al.
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.
Blood.
1995;85:1659-1665 4. Schmitz N, Beksac M, Hasenclever D, et al. A randomized study from the European group for blood and marrow transplantation comparing allogeneic transplantation of filgrastim-mobilized peripheral blood progenitor cells with bone marrow transplantation in 350 patients with leukemia [abstract]. Blood. 2000;96:481a. 5. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 1998;22:1145-1151[CrossRef][Medline] [Order article via Infotrieve].
6.
Champlin RE, Schmitz N, Horowitz MM, et al.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation.
Blood.
2000;95:3702-3709
7.
Blaise D, Kuentz M, Fortanier C, et al.
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle.
J Clin Oncol.
2000;18:537-546 8. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355:1231-1237[CrossRef][Medline] [Order article via Infotrieve].
9.
Bensinger WI, Martin PJ, Storer B, et al.
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
N Engl J Med.
2001;344:175-188 10. Durrant ST, Morton AJ. A randomised trial of filgrastim stimulated donor marrow versus peripheral blood for allogeneic transplantation: increased extensive chronic graft versus host disease following peripheral blood transplantation [abstract]. Blood. 1999;94:608a.
11.
Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH.
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.
J Clin Oncol.
2001;19:3685-3691
12.
Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H.
Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow.
Blood.
1996;88:2775-2779 13. Tayebi H, Kuttler F, Saas P, et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol. 2001;29:458-470[CrossRef][Medline] [Order article via Infotrieve]. 14. Tayebi H, Lapierre V, Saas P, et al. Enhanced activation of B-cells in a G-CSF-mobilized peripheral blood stem cell graft. Br J Haematol. 2001;114:698-700[CrossRef][Medline] [Order article via Infotrieve]. 15. Tayebi H, Tiberghien P, Ferrand C, et al. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Bone Marrow Transplant. 2001;27:167-175[CrossRef][Medline] [Order article via Infotrieve].
16.
Lapierre V, Oubouzar N, Auperin A, et al.
Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation.
Blood.
2001;97:2580-2586
17.
Storek J, Dawson MA, Storer B, et al.
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.
Blood.
2001;97:3380-3389 18. Laurencet FM, Samii K, Bressoud A, et al. Massive delayed hemolysis following peripheral blood stem cell transplantation with minor ABO incompatibility. Hematol Cell Ther. 1997;39:159-162[CrossRef][Medline] [Order article via Infotrieve].
19.
Toren A, Dacosta Y, Manny N, Varadi G, Or R, Nagler A.
Passenger B-lymphocyte-induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation [letter].
Blood.
1996;87:843-844 20. Oziel-Taieb S, Faucher-Barbey C, Chabannon C, et al. Early and fatal immune haemolysis after so-called `minor' ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant. 1997;19:1155-1156[CrossRef][Medline] [Order article via Infotrieve]. 21. Moog R, Melder C, Prumbaum M, Muller N, Schaefer UW. Rapid donor type isoagglutinin production after allogeneic peripheral progenitor cell transplantation. Beitr Infusionsther Transfusionsmed. 1997;34:150-152[Medline] [Order article via Infotrieve]. 22. Salmon JP, Michaux S, Hermanne JP, et al. Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Transfusion. 1999;39:824-827[CrossRef][Medline] [Order article via Infotrieve]. 23. Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol. 2001;112:787-795[CrossRef][Medline] [Order article via Infotrieve]. 24. Lapierre V, Kuentz M, Tiberghien P. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant. 2000;25:507-512[CrossRef][Medline] [Order article via Infotrieve]. 25. Terasaki PI, Bemoco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C and -D antigens. Am J Clin Pathol. 1978;69:103-120[Medline] [Order article via Infotrieve]. 26. Sumitran-Karuppan S, Moller E. The use of magnetic beads coated with soluble HLA class I or class II proteins in antibody screening and for specificity determinations of donor-reactive antibodies. Transplantation. 1996;61:1539-1545[CrossRef][Medline] [Order article via Infotrieve]. 27. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol. 1998;59:313-322[CrossRef][Medline] [Order article via Infotrieve]. 28. Rebibou JM, Chabod J, Bittencourt MC, et al. Flow-PRA evaluation for antibody screening in patients awaiting kidney transplantation. Transpl Immunol. 2000;8:125-128[CrossRef][Medline] [Order article via Infotrieve]. 29. Rose HM, Ragan C, Pearce E, Lipman MO. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med. 1948;68:1-11[CrossRef][Medline] [Order article via Infotrieve]. 30. Anderson SG, Bentzon MW, Houba V, Krag P. International reference preparation of rheumatoid arthritis serum. Bull World Health Organ. 1970;42:311-318[Medline] [Order article via Infotrieve]. 31. Abou-Elella AA, Camarillo TA, Allen MB, et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion. 1995;35:931-935[CrossRef][Medline] [Order article via Infotrieve]. 32. Rosenthal GJ, Weigand GW, Germolec DR, Blank JA, Luster MI. Suppression of B cell function by methotrexate and trimetrexate: evidence for inhibition of purine biosynthesis as a major mechanism of action. J Immunol. 1988;141:410-416[Abstract].
33.
Jensen GS, Mant MJ, Belch AJ, Berenson JR, Ruether BA, Pilarski LM.
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.
Blood.
1991;78:711-719 34. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma: a continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am. 1992;6:297-322[Medline] [Order article via Infotrieve]. 35. Morikawa K, Miyawaki T, Oseko F, Morikawa S, Imai K. G-CSF enhances the immunoglobulin generation rather than the proliferation of human B lymphocytes. Eur J Haematol. 1993;51:144-151[Medline] [Order article via Infotrieve].
36.
Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL.
Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
Blood.
1995;86:4422-4429
37.
Hartung T, Döcke WD, Gantner F, et al.
Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers.
Blood.
1995;85:2482-2489
38.
Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T.
Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma.
Blood.
2000;95:270-276
39.
Mielcarek M, Graf L, Johnson G, Torok-Storb B.
Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation.
Blood.
1998;92:215-222
40.
Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C.
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells.
Blood.
2000;95:2484-2490
41.
Volpi I, Perruccio K, Tosti A, et al.
Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants.
Blood.
2001;97:2514-2521 42. Sullivan KM. Graft-versus-host disease. In: Forman SG,Blum KG,Thomas ED, eds. Bone Marrow Transplantation. Boston, MA: Blackwell; 1995:333-362.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Sundin, O. Ringden, B. Sundberg, S. Nava, C. Gotherstrom, and K. Le Blanc No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients Haematologica, September 1, 2007; 92(9): 1208 - 1215. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
1 of transplantation), the first HSC harvest was
performed by apheresis. If CD34+ cell counts in the
HSC bag were less than 4 × 106/kg recipient body weight,
a second harvest was performed on the sixth day. G-CSF was administered
on the sixth day if a third harvest was required at day +1. GvHD
prophylaxis consisted of cyclosporin A (initiated at day 
at least in part
(IFN-
production